|Bid||72.86 x 100|
|Ask||73.20 x 200|
|Day's Range||72.73 - 75.61|
|52 Week Range||63.76 - 89.54|
|PE Ratio (TTM)||20.75|
|Forward Dividend & Yield||2.28 (2.98%)|
|1y Target Est||N/A|
A German biotech with the potential to rival Gilead, Novartis and Celgene in cancer drugs is looking to file an IPO in the U.S.
A dozen drugs launching in 2018 from heavy-hitters like Roche, Gilead and J&J are expected to hit blockbuster status over the next five years, an analytics firm predicted Thursday.
Geron (GERN) is a biopharmaceutical company supporting the clinical stage development of imetelstat, a telomerase inhibitor by Janssen Biotech. Early clinical data suggest that imetelstat may have disease-modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases. Geron entered into a collaboration agreement with Janssen Biotech in November 2014.
In January, GlaxoSmithKline's (GSK.L) new head of pharmaceuticals Luke Miels issued a blunt challenge to his managers: find budget savings of 20 percent. Miels - a long-time protege of AstraZeneca (AZN.L) CEO Pascal Soriot, whose departure sparked a legal spat between the rival drugmakers - is a key lieutenant for Walmsley as she tries to overhaul the core pharma business. The unit has lagged rivals like Novartis (NOVN.S) and Merck & Co (MRK.N) in producing multibillion-dollar blockbusters, so Walmsley has prioritised plans to refocus both its research and marketing efforts in a drive for fewer but bigger new drugs.
In January, GlaxoSmithKline's new head of pharmaceuticals Luke Miels issued a blunt challenge to his managers: find budget savings of 20 percent. Miels - a long-time protege of AstraZeneca CEO Pascal Soriot, whose departure sparked a legal spat between the rival drugmakers - is a key lieutenant for Walmsley as she tries to overhaul the core pharma business.
After being the only one to finish 2016 in the red, the healthcare sector made a comeback in 2017 and finished the year up 21.7%, barely lagging the S&P 500’s (SPX) 21.83% increase. It’s still early in ...
Let's see if Gilead Sciences Inc. (GILD) stock is a good choice for value-oriented investors right now from multiple angles.
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Seana Smith live from the floor of the New York Stock Exchange to discuss the latest market moves.